BREAST is a leading peer-reviewed journal dedicated to advancing knowledge and practice in the fields of cancer research, oncology, and surgery, published by Churchill Livingstone. With an impressive impact factor and a prestigious Q1 ranking in multiple categories including Cancer Research, Medicine, and Surgery, the journal consistently delivers high-quality content that informs and inspires researchers, clinicians, and educators. Since its transition to Open Access in 2020, BREAST has significantly expanded its reach, providing immediate and unrestricted access to pivotal studies and findings in breast health and disease management. With a history dating back to 1992 and converging to 2024, the journal serves as an essential resource for the latest developments and innovative approaches in the clinical and biomedical aspects of breast care. Scholars and professionals alike can explore a wealth of research aimed at improving patient outcomes and fostering scientific dialogue in this vital area of healthcare.

The Lancet Oncology is a premier peer-reviewed journal published by Elsevier Science Inc., recognized as a leading authority in the field of oncology. With an ISSN of 1470-2045 and E-ISSN 1474-5488, this esteemed journal boasts an impressive 2023 impact factor placing it in the Q1 category of oncology—reflecting its role as a critical resource for cutting-edge research. The journal publishes high-quality articles covering novel scientific discoveries, clinical advancements, and public health issues related to cancer treatment and prevention. It is ranked #5 out of 404 in the Scopus Medicine _ Oncology category, demonstrating its influence and relevance in the field, with an outstanding rank in the 98th percentile. Operating from its base in the United Kingdom, The Lancet Oncology spans a comprehensive timeframe from 2000 to 2024, making it a vital repository of oncology literature. Although it does not primarily operate on an open-access model, its significant subscription base ensures that a wealth of knowledge is accessible to researchers, professionals, and students alike, fostering a profound understanding and advancement in oncology.

Cancer Treatment Reviews, published by Elsevier Science Ltd, is a leading international journal dedicated to the exploration and advancement of therapeutic strategies in oncology. With an impressive impact factor that reflects its status in the field, this journal is classified within Q1 quartile rankings in Medicine (Miscellaneous), Oncology, and Radiology, Nuclear Medicine and Imaging, as of 2023. The journal has a rich lineage, having been established in 1974 and consistently evolving to encompass the latest breakthroughs and methodologies in cancer treatment. A vital resource for researchers, clinicians, and students alike, it aims to promote understanding and application of effective interventions, thereby contributing to improvements in patient outcomes. By prioritizing high-quality reviews, Cancer Treatment Reviews plays an essential role in bridging the gap between current research and clinical practice, making it an indispensable asset in the continuous fight against cancer.

Current Hematologic Malignancy Reports is a significant journal published by the CURRENT MEDICINE GROUP, dedicated to advancing the field of hematology and oncology. With an impressive categorization in the Q1 and Q2 quartiles reflecting its influence and quality—ranked 39th in Medicine Hematology and 129th in Medicine Oncology—it aims to provide a critical platform for the dissemination of innovative research and insights related to hematologic malignancies. Since its inception in 2006, this journal has served as a vital resource for researchers, clinicians, and students alike, fostering collaborative discussions and the exchange of knowledge that can drive improvements in patient care and treatment outcomes. The journal is not currently open-access, ensuring a curated selection of high-quality articles that are peer-reviewed for the enrichment of its readership. The address for correspondence is 400 Market Street, Ste 700, Philadelphia, PA 19106, United States. Its robust impact within the community is showcased through its competitive Scopus rankings, further establishing its importance in ongoing scientific discourse.

Current Rheumatology Reports is a premier journal dedicated to advancing the field of rheumatology, published by Springer. With an esteemed Q1 category ranking in Rheumatology as of 2023 and a remarkable Scopus rank of 6 out of 73, this journal stands at the forefront of research dissemination, boasting an impressive percentile ranking in the 92nd. Since its inception in 1999, Current Rheumatology Reports has provided a critical platform for the latest findings in rheumatological diseases, treatment strategies, and clinical practices. Although it currently does not offer Open Access options, the journal's rigorous peer-review process ensures high-quality publications that are essential for researchers, clinicians, and students alike. By keeping the community informed of key developments, this journal plays a vital role in shaping contemporary rheumatological research and practice, thereby facilitating the advancement of patient care worldwide.

Therapeutic Advances in Medical Oncology, an esteemed journal published by SAGE Publications Ltd, serves as a critical platform for disseminating high-quality research pertinent to the field of oncology. Indexed under the ISSN 1758-8340 and E-ISSN 1758-8359, this Open Access journal has made significant strides since its inception in 2009, attaining a commendable rank of #78 out of 404 in the Medicine - Oncology category of Scopus, placing it in the top 20th percentile of journals. With its category quartile of Q1 established in 2023, it underscores the journal’s commitment to advancing therapeutic approaches in oncology, making it an invaluable resource for researchers, clinicians, and students alike. Offering unrestricted access to pioneering studies since 2017, it aligns with the global movement towards open science, fostering collaboration and innovation among professionals striving to improve cancer treatment outcomes. By bridging the gap between research and clinical practice, Therapeutic Advances in Medical Oncology plays a vital role in shaping the future of cancer therapy.

CA: A Cancer Journal for Clinicians is a prestigious academic journal published by Wiley, serving as a leading source of evidence-based information for those in the fields of oncology and hematology. With an impressive impact factor and ranked in the top quartile (Q1) for both specialties, this journal aims to bridge the gap between the latest research findings and clinical practice. Established in 1950, it boasts a long-standing history of delivering essential insights, guidelines, and innovative strategies to healthcare professionals worldwide, making significant contributions to the understanding and treatment of cancer. Although it does not offer open access, its published content is crucial for researchers, clinicians, and students dedicated to advancing cancer care. The journal's commitment to excellence is reflected in its elite rankings, holding the #1 position in both the Medicine – Oncology and Medicine – Hematology categories according to Scopus, positioning it in the 99th percentile of scholarly impact.

ESMO Open is a premier open-access journal published by Elsevier, dedicated to advancing research in the fields of cancer and oncology. Since its inception in 2016, the journal has established itself as a vital resource for researchers, clinicians, and healthcare professionals, providing a platform for disseminating high-quality, peer-reviewed research. With an impressive Q1 ranking in both Cancer Research and Oncology based on the 2023 category quartiles, ESMO Open ranks within the top tier of its field, showcasing its commitment to excellence and innovation. The journal’s inclusion in Scopus rankings further emphasizes its significant impact, with remarkable placements in the 88th and 83rd percentiles for Oncology and Cancer Research, respectively. Operating under an open access model, ESMO Open ensures that cutting-edge findings and insights are readily available to the global academic community, fostering collaboration and knowledge-sharing to further enhance the understanding and treatment of cancer.

Tumori Journal is a distinguished publication in the field of oncology, dedicated to advancing the understanding and treatment of cancer since its inception in 1946. Published by SAGE Publications Ltd, this Italian journal serves as a pivotal platform for researchers, clinicians, and academicians to disseminate cutting-edge findings in cancer research and related areas of medicine. With an impressive record of contributions spanning multiple decades, Tumori Journal aims to foster collaboration and dialogue among professionals in the oncology community. Although classified in the Q4 category for Cancer Research and the Q3 category for both Medicine (miscellaneous) and Oncology as of 2023, the journal continues to draw interest with its rigorous peer-review process and commitment to quality. Researchers are encouraged to explore innovative methodologies and share impactful clinical insights through the journal, which also ranks within the top tiers of Scopus metrics for oncology and cancer research domains. With a growing emphasis on accessible research, Tumori Journal remains an essential resource in the continuous fight against cancer.

Surgical Oncology-Oxford is a prestigious academic journal published by Elsevier Science Ltd, dedicated to advancing the field of surgical oncology. Since its establishment in 1992, the journal has provided a vital platform for disseminating cutting-edge research, clinical advancements, and innovative surgical techniques. With a focus on both surgery and oncology, the journal is ranked in the Q2 category in Surgery and Q3 in Oncology for 2023, reflecting its commitment to quality and impactful contributions. It ranks #107 out of 551 in Medicine_Surgery and #184 out of 404 in Medicine_Oncology as per Scopus metrics, illustrating its significant role in the academic landscape. Although it does not currently offer open access options, the journal's rigorous peer-review process ensures that only the highest quality research is published. By examining the latest surgical methodologies and oncological insights, Surgical Oncology-Oxford plays a crucial role in enhancing clinical practice and improving patient outcomes, making it an essential resource for researchers, healthcare professionals, and students aiming to stay at the forefront of the field.